Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME. The investigators will be evaluating patients (1-7 days) post injections for: 1. Intraocular inflammation (defined as anterior chamber and/or vitreous cells 2. Pain (as measured on a standardized pain scale).
Epistemonikos ID: 68f558bcf92660731178bc628f121a2286d915b8
First added on: May 12, 2024